Table II.
Primary and secondary antibodies used in the present study.
| Antibody | Cat. no. | Source | Dilution |
|---|---|---|---|
| Primary antibodies | |||
| TGF-β1 | ab9758 | Abcam, Cambridge, UK | 1:100 |
| Lyn/p-Lyn | #2732S/2731S | Cell Signaling Technologies, Inc., Beverly, MA, USA | 1:1,000 |
| Syk/p-Syk | sc-1077/sc293118 | Santa Cruz Biotechnology, Inc., Dallas, TX, USA | 1:1,000 |
| ERK/p-ERK | #9102/#9101S | Cell Signaling Technologies, Inc. | 1:1,000 |
| JNK/p-JNK | #9151S/#9251S | Cell Signaling Technologies, Inc., | 1:1,000 |
| p38/p-p38 | #9212/#9211S | Cell Signaling Technologies, Inc., | 1:1,000 |
| PI3K/p-PI3K | #4292S/#4228S | Cell Signaling Technologies, Inc., | 1:1,000 |
| Akt/p-Akt | #9272/#9271S | Cell Signaling Technologies, Inc., | 1:1,000 |
| IκBα/p-IκBα | #9242/#9246S | Cell Signaling Technologies, Inc., | 1:1,000 |
| β-actin | sc-47778 | Santa Cruz Biotechnology, Inc. | 1:1,000 |
| Secondary antibodies | |||
| Goat anti-rabbit IgG, pAb | ADI-SAB-300-J | Enzo Life Sciences, Inc., Farmingdale, NY, USA | 1:5,000 |
| Goat anti-mouse IgG, pAb | ADI-SAB-100-J | Enzo Life Sciences, Inc. | 1:2,500 |
TGF-β1, transforming growth factor-β1; Lyn, Lck/yes-related novel tyrosine kinase; Syk, spleen tyrosine kinase; ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal kinase; PI3K, phosphatidylinositol 3-kinase; p-, phosphorylated; IgG, immunoglobulin G; pAb, polyclonal antibody.